Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Compass Point Downgrades Centerspace to Neutral, Announces $75 Price Target

Compass Point Downgrades Centerspace to Neutral, Announces $75 Price Target

Compass Point analyst Merrill Ross downgrades Centerspace (NYSE:CSR) from Buy to Neutral and announces $75 price target.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Compass Point analyst Merrill Ross downgrades Centerspace (NYSE:CSR) from Buy to Neutral and announces $75 price target.

Analyst Ratings

Analyst Ratings for Bumble

By Benzinga Insights

June 21, 2:01 PM

Analysts have provided the following ratings for Bumble (NASDAQ:BMBL) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BMBL

Analyst Ratings

Analyst Ratings for Compass Minerals Intl

By Benzinga Insights

July 19, 8:00 AM

Over the past 3 months, 4 analysts have published their opinion on Compass Minerals Intl (NYSE:CMP) stock. These…

CMP

Avicanna Launches A Medical Cannabis Education Portal For Health Care Professionals

By Vuk Zdinjak

October 18, 11:15 AM

Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) has launched its medical cannabis education portal, ”Avicenna Academy”, a no-cost resource and medical education portal for health care professionals.

AVCNF

Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

By Benzinga Newsdesk

February 23, 5:10 AM

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

IONS

Compass Point Downgrades Centerspace to Neutral, Announces $75 Price Target

Related Posts

Analyst Ratings for Bumble

Analyst Ratings for Compass Minerals Intl

Avicanna Launches A Medical Cannabis Education Portal For Health Care Professionals

Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target